Dr. Chi-Wei Chang, a highly-experienced radiochemist in the field of radiopharmaceuticals in Taiwan, has been dedicated in the field of positron radiopharmaceutical synthesis for more than 30 years and had received a Ph. D of the department of Biomedical Imaging and Radiological Sciences in National Yang-Ming University (it’s now renamed as National Yang-Ming Chiao-Tung University) in 2009. Dr. Chang not only has remarkable achievements in developing novel radiopharmaceuticals, but also brought into realization of turning complicated handworked-synthesized radiopharmaceutical manufacturing to fully automatic procedure, which is a very distinction accomplishment in the field of radiopharmaceutical in Taiwan.

During his service in Taipei Veteran General Hospital (VGHTPE), Dr. Chang served as the chief leader of pharmaceutical production team of nuclear medicine. He is the principal investigator of more than 20 government academic programs, and had obtained grants for over ten million NT dollars. As the pioneer of the team of pharmaceutical production in VGHTPE nuclear medicine department, Dr. Chi-Wei Chang has had led the group in fulfilling the accomplishment of automatic-synthesis of imaging agents of prostatic cancer, BNCT and tau protein/beta amyloid, an agent used for the diagnosis of Alzheimer’s disease, which brings enormous benefits to all the patients who suffer from cancer and senile dementia. 

 “Regulations on Good Practices for Positron Emission Tomography Drug Dispensation” has been legislated in Taiwan, which imposed great restriction on the radiopharmaceutical offering by medical-institutes. Under this very circumstances, teaming up with the co-founder & CEO of Primo Biotechnology, Dr. Ya-Yao Huang, Dr. Chang works in collaboration with Dr. Huang, both are outstanding radiochemists devoted in the healthcare system for years, to put the radiopharmaceutical production and application in a larger scale, which are once medical center-limited.

For providing the best well-being to the vast patients, Primo Biotechnology is aiming at the popularization and expansion of radiopharmaceutical research, synthesis and development.